Key facts
- WeHand-Bio’s last known valuation is $566.6M (Sep 2025).
- It has raised $162.0M; the latest was IPO in Feb 2026.
- Notable investors include Cowin Capital, Shun Xi Fund, Lapam Capital, Zero2IPO Venture Capital, Beishang Capital Management (Beijing) — 10 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for WeHand-Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for WeHand-Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About WeHand-Bio
Developer and manufacturer of first-in-class natural drug innovations and advanced drug delivery systems designed for the treatment of complex metabolic disorders, malignant tumors, and inflammatory-immune diseases. The company provides multi-component synergistic therapies and precision targeted release platforms, enabling patients and clinicians with enhanced safety, efficacy, and systemic regulatory solutions for difficult-to-treat conditions.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2010
- Employees
- 535
- Website
- wehandbio.com/
- Ownership
- In IPO Registration
WeHand-Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in WeHand-Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on WeHand-Bio in its N-PORT filings yet. We sweep new filings monthly.